Article

In The Literature: MicroRNA Biomarkers Could Predict Chemotherapy Response in Lung Cancer

MicroRNAs have the potential to be predictive biomarkers that can predict survival as well as response to chemotherapy, as this study discovered.

Tumor samples from recurrent lung adenocarcinoma patients treated with platinum-based doublet chemotherapy were analyzed for microRNA expression. The analysis identified a signature: miR1290, miR196b, and miR135a*. These 3 microRNAs could predict chemotherapy response, not progression-free survival or overall survival, in patients with recurrent lung cancer.

Link to the abstract in Clinical Cancer Research: http://bit.ly/1m5Ed8v

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
CK Wang, MD, COTA
Eric Lander, MD
Eric Lander, MD
David Awad, PharmD, BCOP
Andrew Evens, DO, MBA, MSc, deputy director for clinical services and chief physician officer, Rutgers Cancer Institute and Jack & Sheryl Morris Cancer Center
Coral Omene, MD, PhD, sitting for a vieo interview
David Awad, PharmD, BCOP
Coral Omene, MD, PhD, sitting for a vieo interview
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo